menu

The Itch Clinic: Treatment of Chronic Kidney Disease-Associated Pruritus in Hemodialysis Patients – Real-World Cases

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

The Itch Clinic: Treatment of Chronic Kidney Disease-Associated Pruritus in Hemodialysis Patients – Real-World Cases

0.50 credits
ReachMD Healthcare Image
Restart
Resume
Read full article
Choose a format
Get your free creditsSkip straight to the post-test if you have already participated in this activity
Media formats available:
0.50 credits
A pre-test is required to view this content.
A pre-survey is required to view this content.
Details
Presenters
Comments
  • Overview

    At least 25% of patients with chronic kidney disease (CKD), and between 50% to 86% of patients with CKD on dialysis suffer from CKD-associated pruritus (CKD-aP). The itch can substantially interfere with sleep and quality of life and has been linked with depression, fatigue, and isolation. There are at least 4 pathways that have been hypothesized as possible etiologies of CKD-aP, leading to a wide range of potential therapeutic strategies for the itch. Difelikefalin is the first agent FDA-approved specifically for the treatment of moderate-to-severe pruritus in CKD patients undergoing dialysis; it is a peripheral kappa-opioid receptor agonist that targets the opioid dysregulation theory. It is imperative that all clinicians involved in the care of patients with CKD routinely inquire about pruritus and adequately treat their patients for CKD-aP.  This case-based program will apply the foundational information presented in the first program of this 2-part series to real-world patients.

  • Disclosure of Conflicts of Interest

    Disclosure
    It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with ineligible companies whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are mitigated by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant financial relationships to disclose.

    Faculty
    Dr. Fishbane has disclosed the following relevant financial relationships:
    Consultant and Researcher: Cara Therapeutics
    Dr. Shirazian has disclosed the following relevant financial relationships:
    Advisor: Vifor
    Consultant: CARA
    Speaker: Otsuka, Vifor
    Jennifer Caudle, DO, Host: has no financial relationships to disclose.

    AKH Staff and Planners
    Lynne Kolton Schneider, PhD, Medical Writer/Interviewer: has no financial relationships to disclose.
    Dorothy Caputo, MA, BSN, RN, AKH Director of Accreditation, Planner: has no financial relationships to disclose.
    Bernadette Marie Makar, MSN, NP-C, APRN-C, Nurse Planner/Reviewer: has no financial relationships to disclose.
    Michele Bielarski, RN - Nurse Reviewer: has no financial relationships to disclose.
    Patricia Brignoni, AKH Director of Operations: has no financial relationships to disclose.
    Steve Eckert, AKH President & CEO, Planner: has no financial relationships to disclose.
    All of the relevant financial relationships listed for these individuals have been mitigated.

  • Target Audience

    This educational program will address identified educational and practice gaps among nephrology healthcare providers – physicians, nurses, nurse practitioners (NPs), physician assistants (PAs), and dieticians who care for patients with chronic kidney disease-associated pruritus (CKD-aP).

  • Learning Objectives

    Upon completion of the educational activity, participants should be able to:

    • Review the epidemiology of chronic kidney disease-associated pruritus (CKD-aP)
    • Discuss pathophysiology and pathways associated with chronic kidney disease-associated pruritus (CKD-aP)
    • Review the clinical trial data on emerging treatments for chronic kidney disease-associated pruritus (CKD-aP)
  • Accreditation and Credit Designation Statements

    Credit provided by AKH Inc., Advancing Knowledge in Healthcare
    In support of improving patient care, AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    Physicians
    AKH Inc., Advancing Knowledge in Healthcare designates this enduring material activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Nurses
    0.5 ANCC contact hours

    Physician Assistants

    APA Credit Designation Statement
    AKH Inc., Advancing Knowledge in Healthcare has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credits. Approval is valid until 10/22/2022. PAs should only claim credit commensurate with the extent of their participation.

    Dietitians

    Nurse Practitioners
    AKH Inc., Advancing Knowledge in Healthcare is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 030083. This activity is approved for 0.5 contact hour(s) (which includes 0 hour(s) of pharmacology).

    Disclaimer
    This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant's misunderstanding of the content.

    Disclosure of Unlabeled Use and Investigational Product
    This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Criteria for Success
    To receive credit, participants should review the entire activity, complete and submit posttest and an evaluation. A certificate will be available upon successful completion of the quiz and evaluation. You must participate in the entire activity to receive credit. There is no fee to participate in this activity. If you have questions about this CE activity, please contact AKH Inc. at tbrignoni@akhcme.com.

  • Provider(s)/Educational Partner(s)

  • Commercial Support

    Supported by an educational grant from VIFOR PHARMA, INC.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Recommended
Details
Presenters
Comments
  • Overview

    At least 25% of patients with chronic kidney disease (CKD), and between 50% to 86% of patients with CKD on dialysis suffer from CKD-associated pruritus (CKD-aP). The itch can substantially interfere with sleep and quality of life and has been linked with depression, fatigue, and isolation. There are at least 4 pathways that have been hypothesized as possible etiologies of CKD-aP, leading to a wide range of potential therapeutic strategies for the itch. Difelikefalin is the first agent FDA-approved specifically for the treatment of moderate-to-severe pruritus in CKD patients undergoing dialysis; it is a peripheral kappa-opioid receptor agonist that targets the opioid dysregulation theory. It is imperative that all clinicians involved in the care of patients with CKD routinely inquire about pruritus and adequately treat their patients for CKD-aP.  This case-based program will apply the foundational information presented in the first program of this 2-part series to real-world patients.

  • Disclosure of Conflicts of Interest

    Disclosure
    It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with ineligible companies whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are mitigated by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant financial relationships to disclose.

    Faculty
    Dr. Fishbane has disclosed the following relevant financial relationships:
    Consultant and Researcher: Cara Therapeutics
    Dr. Shirazian has disclosed the following relevant financial relationships:
    Advisor: Vifor
    Consultant: CARA
    Speaker: Otsuka, Vifor
    Jennifer Caudle, DO, Host: has no financial relationships to disclose.

    AKH Staff and Planners
    Lynne Kolton Schneider, PhD, Medical Writer/Interviewer: has no financial relationships to disclose.
    Dorothy Caputo, MA, BSN, RN, AKH Director of Accreditation, Planner: has no financial relationships to disclose.
    Bernadette Marie Makar, MSN, NP-C, APRN-C, Nurse Planner/Reviewer: has no financial relationships to disclose.
    Michele Bielarski, RN - Nurse Reviewer: has no financial relationships to disclose.
    Patricia Brignoni, AKH Director of Operations: has no financial relationships to disclose.
    Steve Eckert, AKH President & CEO, Planner: has no financial relationships to disclose.
    All of the relevant financial relationships listed for these individuals have been mitigated.

  • Target Audience

    This educational program will address identified educational and practice gaps among nephrology healthcare providers – physicians, nurses, nurse practitioners (NPs), physician assistants (PAs), and dieticians who care for patients with chronic kidney disease-associated pruritus (CKD-aP).

  • Learning Objectives

    Upon completion of the educational activity, participants should be able to:

    • Review the epidemiology of chronic kidney disease-associated pruritus (CKD-aP)
    • Discuss pathophysiology and pathways associated with chronic kidney disease-associated pruritus (CKD-aP)
    • Review the clinical trial data on emerging treatments for chronic kidney disease-associated pruritus (CKD-aP)
  • Accreditation and Credit Designation Statements

    Credit provided by AKH Inc., Advancing Knowledge in Healthcare
    In support of improving patient care, AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    Physicians
    AKH Inc., Advancing Knowledge in Healthcare designates this enduring material activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Nurses
    0.5 ANCC contact hours

    Physician Assistants

    APA Credit Designation Statement
    AKH Inc., Advancing Knowledge in Healthcare has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credits. Approval is valid until 10/22/2022. PAs should only claim credit commensurate with the extent of their participation.

    Dietitians

    Nurse Practitioners
    AKH Inc., Advancing Knowledge in Healthcare is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 030083. This activity is approved for 0.5 contact hour(s) (which includes 0 hour(s) of pharmacology).

    Disclaimer
    This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant's misunderstanding of the content.

    Disclosure of Unlabeled Use and Investigational Product
    This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Criteria for Success
    To receive credit, participants should review the entire activity, complete and submit posttest and an evaluation. A certificate will be available upon successful completion of the quiz and evaluation. You must participate in the entire activity to receive credit. There is no fee to participate in this activity. If you have questions about this CE activity, please contact AKH Inc. at tbrignoni@akhcme.com.

  • Provider(s)/Educational Partner(s)

  • Commercial Support

    Supported by an educational grant from VIFOR PHARMA, INC.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Schedule2 Dec 2021
Webpack App